FDA
-
-
-
-
-
-
-
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
-
-
-
-
-
-
-
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
-
-
-
-
-
-
-
Novocure's (NVCR) Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Novocure Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI
-
-
-
-
-
-
-
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
-
-
-
-
-
-
-
NovoCure Investors: August 18, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

